Alcami, a contract development and manufacturing organization (CDMO), recently announced the resignation of its CEO, Bill Humphries. Alcami’s Board Chair and former CEO Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations.
At an investor update at the end of last week, Lonza has announced its "One Lonza" restructuring strategy, which aims to reorganize its CDMO business, simplify its operating model, enhance manufacturing and engineering, and expand its production footprint.
The Italian Olon Group, a leading international supplier of active pharmaceutical ingredients (APIs), presents the 2023 Corporate Sustainability Report and confirms the sustainability journey toward energy transition, investments in alternative energy sources, social and economic involvement and support for the communities in which it operates
The Society of Chemical Manufacturers & Affiliates (SOCMA) has published the results of its 2025 Contract Manufacturing Outlook survey which reveals significant trends and insights into the contract manufacturing landscape.
Lisbon, Portugal-headquartered Hovione has completed significant expansions in Europe and the USA. The investments at the facilities in East Windsor, New Jersey, and Ringaskiddy, Cork, significantly increase the global capacities of the CDMO (contract development and manufacturing organization) for spray drying for pharma applications and improve the sites' capabilities.
Samsung Biologics, a global contract development and manufacturing organization (CDMO), recently announced a series of manufacturing deals with a Europe-based pharmaceutical company.
Avantor has opened its latest Innovation Center in Bridgewater, New Jersey, US, “to support the growing demands for monoclonal antibodies, cell and gene therapy and mRNA workflows.” The new center is now part of the company’s network of 13 global research and innovation centers.
Zofingen, Switzerland-based contract development and manufacturing organization (CDMO) Siegfried inaugurated its new global research and development (R&D) center for drug substances at its site in Evionnaz, Switzerland. The 4,500 m2 center houses chemical and analytical facilities, laboratories, and technologies such as flow chemistry, advanced distillation and process analytical technology, as well as new office space.
Lonza, a global contract development and manufacturing organization (CDMO) for the pharmaceutical, biotech, and nutraceutical markets, announced today that it will invest in additional bioconjugation capabilities in Visp, Switzerland.
US-headquartered Avid Bioservices, a biologics-oriented CDMO, will be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion. The three companies have signed a corresponding agreement.
Belgium-headquartered pharmaceutical contract development and manufacturing organization (CDMO) Ardena announced plans to expand its bioanalytical services in the Netherlands. As part of the investment, the company plans to establish a new bioanalytical laboratory at its Pivot Park facility in Oss, as well as additional capacity and new GLP capabilities at its bioanalytical center of excellence in Assen.
Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), today announced the second phase of an expansion strategy at its Deeside, UK site to support antibody-drug conjugate (ADC) development, with a more than £10 million (€11.9 million) investment to increase GMP bioconjugation capacity.
In a move to further increase production efficiency and modernize the site, German contract development and manufacturing organization (CDMO) Rentschler Biopharma plans to construct a new buffer media station at its company headquarters in Laupheim. According to Rentschler, this is the largest single investment in the German site.
Today, Cambrex announced its stability storage business, Q1 Scientific, and opened a new cGMP facility in Durham, North Carolina, expanding its capacity for environmentally controlled stability storage services to North America's pharmaceutical, medical device, and life sciences industries.
OneSource Specialty Pharma, a newly incorporated CDMO, formed from the merger of three CDMO businesses within the Strides Group. The company has a 30-year track record and specializes in biologics, drug-device combinations, and soft gelatin capsules.
US contract development and manufacturing organization (CDMO) Piramal Pharma Solutions (PPS), part of India-headquartered Piramal Pharma, plans to invest $80 million for the expansion of its Lexington, Kentucky, facility.
Cambrex announced that Snapdragon Chemistry, a Cambrex company, has developed a new liquid-phase peptide synthesis (LPPS) technology utilizing active pharmaceutical ingredient (API) batch reactors and continuous flow.
Lonza and Vertex Pharmaceuticals recently announced a commercial supply agreement for casgevy (exagamglogene autotemcel).
Lonza inaugurated its new facility at the Colmar, France site. The new Innovaform Accelerator will serve as a Center of Excellence for developing and innovating capsule-based manufacturing and delivery solutions for oral and pulmonary administration.
Bill Humphries, CEO of Alcami, shares his vision for the future, discussing dynamic market trends and the company’s commitment to innovation. Under his leadership, Alcami is poised to redefine the pharmaceutical and biotechnology landscape, focusing on cutting-edge solutions and navigating global complexities. This conversation highlights Alcami’s strategic direction, accomplishments, and upcoming challenges.
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Interview with Olivier Lambrechts, executive leadership team member and president NCE at Arxada.
Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs), including several multi-billion large-scale biomanufacturing projects. What companies are expanding, and where do these expansions stand?
CDMO Serán BioScience recently announced that it has completed an expansion to increase the number of process manufacturing suites at its facility in Bend, Oregon, from 6 to 14, adding approximately 130% more cGMP clinical manufacturing capacity.
Olon continues its growth path and increases its total production capacity following the acquisition of Huvepharma Italia and its site in Garessio, Cuneo, in the northwestern part of Italy.
Bora Pharmaceuticals, a Taiwan-headquartered contract development and manufacturing organization (CDMO), has completed the acquisition of Emergent BioSolutions' sterile manufacturing facility in Baltimore-Camden, Maryland, USA. The facility adds drug product fill/finish to Bora’s extensive biologics drug substance capabilities.
A recent report by consulting company WittKiefer delves into the role of CDMOs within the pharmaceutical industry, evaluating the effectiveness of existing leadership structures and expertise in navigating market complexities.
Touchlight, a UK-based custom development and manufacturing organization (CDMO) specializing in enzymatic DNA production, signed a license agreement with British drugmaker GSK which grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA (doggybone DNA) technology for the development and production of mRNA-based products.
Santa Clara, CA-based Agilent Technologies has signed a definitive agreement to acquire specialized contract development and manufacturing organization Biovectra from H.I.G. Capital in a move to expand its end-to-end biopharma solutions.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutical and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer.
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform.
Navin Molecular, an Indian-headquartered CDMO with small molecule development and manufacturing capabilities, recently announced a Rs 288 Crore (approximately €32.6 million/$35 million) investment to construct a 9,000 m2 GMP manufacturing plant in Dewas, India. The new facility will nearly double the overall capacity at the site to 420 m3. It will support existing commercial-scale projects and meet future demands as the company continues to expand its global customer base.
South Korea-headquartered contract development and manufacturing organization (CDMO) SK Bioscience plans to acquire a 60% stake in IDT Biologika, a German CDMO specialized in vaccines, gene and immune therapy and oncolytic viruses, from Klocke Group. Klocke will retain a 40% stake in IDT Biologika and thus remains the company's second-largest shareholder.
US contract development and manufacturing organization (CDMO) Veranova has initiated an expansion of its antibody-drug conjugate (ADC) and highly potent active pharmaceutical ingredient (HPAPI) development and manufacturing capabilities at its US facility in Devens, Massachusetts.
Zofingen, Switzerland-based contract development and manufacturing organization (CDMO) Siegfried has signed a binding agreement to acquire an early-phase CDMO site in Grafton, Wisconsin, US, from Curia. The transaction is expected to close by July 1, subject to customary closing conditions.
